Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial

...

Related Keywords

Canada ,United States ,Gregory Lubiniecki ,Merck Research Laboratories ,European Union ,Youtube ,European Organisation For Research ,Facebook ,Merck Co Inc ,Exchange Commission ,Twitter ,European Commission ,Instagram ,Linkedin ,Statement Of Merck Co Inc ,European Medicines Agency ,Medicinal Products ,Human Use ,Merck Research ,European Organisation ,European Thoracic Oncology Platform ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse Reactions ,Single Agent ,Thyroid Disorders ,Which Can Present With Diabetic Ketoacidosis ,Nervous System ,Connective Tissue ,Patients With Multiple Myeloma ,Neck Squamous Cell Cancer ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient Cancer ,Mismatch Repair Deficient Colorectal Cancer ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,